What's new? Log in Free sign up

Galapagos (GLPG) News and press releases

Company Profile

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Jefferies Upgrades Galapagos to Hold, Lowers Price Target to $47.2

News, Upgrades, Price Target, Analyst Ratings

Jefferies analyst Peter Welford upgrades Galapagos (NASDAQ:GLPG) from Underperform to Hold and lowers the price target from $49 to $47.2.

Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories

Cryptocurrency, Large Cap, News, Penny Stocks, Top Stories, Markets, Tech, Media, General

On A Mission As Top European Player, Galapagos Looks For Acquisition Targets

Biotech, M&A, News, Health Care, Rumors, Media, General

Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development.

Financial Times Reported Earlier Belgian Biotech Company Galapagos on the Hunt for Deals

https://www.ft.com/content/06c089ca-8810-493d-ab40-c3fa02ff8779

Galapagos And CellPoint Presented Initial Data At ASH 2022 For GLPG5101, A CD19 CAR-T Candidate Manufactured At Point-Of-Care

Biotech, News, FDA, Events, General

6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR) No grade 3 or higher cytokine

Stocks That Hit 52-Week Lows On Friday

On Friday, 127 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

Wednesday saw 219 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 167 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 160 companies set new 52-week lows.

Galapagos To Present Encouraging Initial Data From FILOSOPHY Real-World Arthritis Study At ACR Convergence 2022

Biotech, News, FDA, Events, General

Preliminary results from real-world FILOSOPHY, FILgotinib Observational Study Of Patient Health-related outcomes, in the first 200 patients with moderately to severely active rheumatoid arthritis (RA) Data

Where Galapagos Stands With Analysts

Analyst Ratings

Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter:

RBC Capital Maintains Sector Perform on Galapagos, Lowers Price Target to $53

News, Price Target, Analyst Ratings

RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and lowers the price target from $55 to $53.

Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Galapagos, Lowers Price Target to $57

News, Price Target, Analyst Ratings

Morgan Stanley analyst Matthew Harrison maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and lowers the price target from $63 to $57.

Raymond James Downgrades Galapagos to Market Perform

News, Downgrades, Analyst Ratings

Raymond James analyst Dane Leone downgrades Galapagos (NASDAQ:GLPG) from Outperform to Market Perform.

After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns

Biotech, Large Cap, News, Health Care, FDA, General

Press releases

From Benzinga Pro

Galapagos receives transparency notification from FMR LLC

News, Press Releases

Mechelen, Belgium; 10 January 2023, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1,

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

News, Press Releases

Mechelen, Belgium; 3 January 2023, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023. Paul Stoffels1, CEO, will present on

Galapagos receives transparency notification from FMR LLC

News, Press Releases

Mechelen, Belgium; 23 December 2022, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1,

Galapagos announces changes to Executive Committee

News, Press Releases

Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

News, Press Releases

6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR)No grade 3 or higher cytokine release

Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Supportive outcome for Jyseleca as treatment option with a positive benefit/risk profile after review of safety data of all JAK inhibitors approved in Europe for treatment of inflammatory conditions This follows the

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Preliminary results from real-world FILOSOPHY, FILgotinib Observational Study Of Patient Health-related outcomes, in the first 200 patients with moderately to severely active rheumatoid arthritis (RA)Data showed that

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

News, Press Releases

Guiding principles for a sustainable future: Invest in strategic therapeutic areas of oncology and immunologyRebuild and accelerate portfolio of transformational medicines in high unmet medical needsCombine internal

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncologyJyseleca® 2022 net sales